Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Originally published in Science Express on 14 August 2003
Science 12 September 2003:
Vol. 301. no. 5639, pp. 1535 - 1537
DOI: 10.1126/science.1086845
Prev | Table of Contents | Next

Reports

Antiretroviral Drugs for Tuberculosis Control in the Era of HIV/AIDS

Brian G. Williams* and Christopher Dye

Human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) has dramatically increased the incidence of tuberculosis (TB) in subSaharan Africa, where up to 60% of TB patients are coinfected with HIV and each year 200,000 TB deaths are attributable to HIV coinfection. Now HIV threatens control of TB in Asia, Eastern Europe, and Latin America. Antiretroviral (ARV) drugs can prevent TB by preserving immunity, but cohort analysis shows that early therapy, plus high levels of coverage and compliance, will be needed to avert a significant fraction of TB cases. However, ARV drugs could enhance the treatment of TB, and TB programs provide an important entry point for the treatment of HIV/AIDS.

Communicable Diseases, World Health Organization, 1211 Geneva 27, Switzerland.

* To whom correspondence should be addressed. E-mail: williamsbg{at}who.int

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Opportunities and Challenges for HIV Care in Overlapping HIV and TB Epidemics.
D. V. Havlir, H. Getahun, I. Sanne, and P. Nunn (2008)
JAMA 300, 423-430
   Abstract »    Full Text »    PDF »
Immune Reconstitution and "Unmasking" of Tuberculosis during Antiretroviral Therapy.
S. D. Lawn, R. J. Wilkinson, M. C. I. Lipman, and R. Wood (2008)
Am. J. Respir. Crit. Care Med. 177, 680-685
   Abstract »    Full Text »    PDF »
HIV Impairs TNF-{alpha} Mediated Macrophage Apoptotic Response to Mycobacterium tuberculosis.
N. R. Patel, J. Zhu, S. D. Tachado, J. Zhang, Z. Wan, J. Saukkonen, and H. Koziel (2007)
J. Immunol. 179, 6973-6980
   Abstract »    Full Text »    PDF »
Quantitative Impact of Human Immunodeficiency Virus Infection on Tuberculosis Dynamics.
K. DeRiemer, L. M. Kawamura, P. C. Hopewell, and C. L. Daley (2007)
Am. J. Respir. Crit. Care Med. 176, 936-944
   Abstract »    Full Text »    PDF »
Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations.
T. Cohen, M. Lipsitch, R. P. Walensky, and M. Murray (2006)
PNAS 103, 7042-7047
   Abstract »    Full Text »    PDF »
The impact of HIV/AIDS on the control of tuberculosis in India.
B. G. Williams, R. Granich, L. S. Chauhan, N. S. Dharmshaktu, and C. Dye (2005)
PNAS 102, 9619-9624
   Abstract »    Full Text »    PDF »
Evolution of Tuberculosis Control and Prospects for Reducing Tuberculosis Incidence, Prevalence, and Deaths Globally.
C. Dye, C. J. Watt, D. M. Bleed, S. M. Hosseini, and M. C. Raviglione (2005)
JAMA 293, 2767-2775
   Abstract »    Full Text »    PDF »
New Small-Molecule Synthetic Antimycobacterials.
L. Ballell, R. A. Field, K. Duncan, and R. J. Young (2005)
Antimicrob. Agents Chemother. 49, 2153-2163
   Full Text »    PDF »
Can Treating AIDS Prevent TB?.
(2003)
Journal Watch Infectious Diseases 2003, 4
   Full Text »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)